ESMO 2023 | Assessing the rate of relapse in head and neck cancer with HPV cfDNA

Jens Peter Klussmann, MD, University of Cologne, Cologne, Germany, comments on detecting relapse in patients with human papilloma virus (HPV)-positive head and neck cancer by monitoring levels of HPV cell free DNA (cfDNA). Patients who have persistent levels of HPV cfDNA are found to have higher rates of relapse and prospective trials are underway to further assess this correlation. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.